{"concreteType":"org.sagebionetworks.repo.model.table.QueryResultBundle","queryResult":{"concreteType":"org.sagebionetworks.repo.model.table.QueryResult","queryResults":{"concreteType":"org.sagebionetworks.repo.model.table.RowSet","tableId":"syn16857542","etag":"b84958ba-d4d2-4f71-bd07-3652d21ca6a8","headers":[{"name":"projectName","columnType":"STRING","id":"70035"},{"name":"id","columnType":"ENTITYID","id":"70408"},{"name":"fundingAgency","columnType":"STRING","id":"62359"},{"name":"citation","columnType":"STRING","id":"70409"},{"name":"doi","columnType":"STRING","id":"70037"},{"name":"tumorType","columnType":"STRING","id":"39539"},{"name":"diseaseFocus","columnType":"STRING","id":"62360"},{"name":"featured","columnType":"STRING","id":"71578"}],"rows":[{"rowId":2,"versionNumber":17,"values":["Child NF1 Quality of Life Measures","syn4939878","NTAP","Nutakki K et al. Development of the pediatric quality of life inventory neurofibromatosis type 1 module items for children, adolescents and young adults: qualitative methods. J Neurooncol (2017)","10.1007/s11060-016-2351-2","Plexiform Neurofibroma","Neurofibromatosis 1",null]},{"rowId":3,"versionNumber":17,"values":["Child NF1 Quality of Life Measures","syn4939878","NTAP","Draucker CB et al. The health-related quality of life of children, adolescents, and young adults with neurofibromatosis type 1 and their families: Analysis of narratives. J Spec Pediatr Nurs (2017).","10.1111/jspn.12174","Plexiform Neurofibroma","Neurofibromatosis 1",null]},{"rowId":4,"versionNumber":20,"values":["Drug Screening of pNF Cell Lines","syn4939906","NTAP","Ferrer M, et al. Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells. Nature Sci Data (2018).","10.1038/sdata.2018.106","Plexiform Neurofibroma","Neurofibromatosis 1","yes"]},{"rowId":5,"versionNumber":12,"values":["NF1 Dermal Neurofibroma Longitudinal Natural History Study and Selumetinib Clinical Trial","syn8012530","NTAP","Cannon A, et al. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study. Orphanet J Rare Dis (2018).","10.1186/s13023-018-0772-z","Cutaneous Neurofibroma","Neurofibromatosis 1",null]},{"rowId":11,"versionNumber":12,"values":["Plexiform Neurofibroma Model Systems for Preclinical Drug Screening","syn7217928","NTAP","Brock EJ, Ji K, Reiners JJ Jr. & Mattingly RR. How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization. Mini Rev Med Chem. 2016 ; 16(5): 358-369.","10.2174/1389557515666151001154002","Plexiform Neurofibroma","Neurofibromatosis 1",null]},{"rowId":12,"versionNumber":12,"values":["pNF Cell Line Characterization Studies","syn4939874","NTAP","Ferrer M, et al. Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells. Nature Sci Data (2018).","10.1038/sdata.2018.106","Plexiform Neurofibroma","Neurofibromatosis 1",null]},{"rowId":16,"versionNumber":12,"values":["Development of Patient Reported Outcomes System","syn4939888","NTAP","Lai, JS, et al. Using a qualitative approach to conceptualize concerns of patients with neurofibromatosis Type 1 associated plexiform neurofibromas (pNF) across the lifespan. J. American Journal of Medical Genetics Part A. 2017 173(1), 79-87. ","10.1002/ajmg.a.37987","Plexiform Neurofibroma","Neurofibromatosis 1",null]},{"rowId":17,"versionNumber":12,"values":["Development of Patient Reported Outcomes System","syn4939888","NTAP","Patel ZS, et al.Considerations for conducting qualitative research with pediatric patients for the purpose of PRO development.  Quality of Life Research, 2016; 25, 2193-2199.   ","10.1007/s11136-016-1256-z","Plexiform Neurofibroma","Neurofibromatosis 1",null]},{"rowId":18,"versionNumber":12,"values":["Development of Patient Reported Outcomes System","syn4939888","NTAP","Jensen, SE, et al. (in press) Lifespan Development: Symptoms Experienced by Individuals with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas from Childhood into Adulthood. Journal of Clinical Psychology in Medical Settings. ",null,"Plexiform Neurofibroma","Neurofibromatosis 1",null]},{"rowId":19,"versionNumber":12,"values":["Development of Patient Reported Outcomes System","syn4939888","NTAP","Lai, J-S., et al. (in press). PROMIS and Neuro-QoL to Evaluate Quality of Life for Children and Adolescents with Neurofibromatosis Type 1 Associated Plexiform Neurofibroma. Journal of Pediatrics. ",null,"Plexiform Neurofibroma","Neurofibromatosis 1",null]},{"rowId":21,"versionNumber":12,"values":["Development and Validation of PRO Measures to Assess Pain in Individuals with NF1 and pNF","syn4939912","NTAP","Walsh, KS et al.  for the REiNS International Collaboration.  Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention. Neurology. 2016 August 16; 87(7 Suppl 1):  S21-30.  ","10.1212/WNL.0000000000002928","Plexiform Neurofibroma","Neurofibromatosis 1",null]},{"rowId":22,"versionNumber":12,"values":["Development and Validation of PRO Measures to Assess Pain in Individuals with NF1 and pNF","syn4939912","NTAP","Wolters, PL et al. for the REiNS International Collaboration. Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials. Neurology. 2016 Aug 16;87(7 Suppl 1):S4-S12.","10.1212/WNL.0000000000002927","Plexiform Neurofibroma","Neurofibromatosis 1",null]},{"rowId":23,"versionNumber":12,"values":["Acceptance and Commitment Therapy in NF1","syn4939896","NTAP","Allen, TM et al. The Relationship Between Heart Rate Variability, Psychological Flexibility, and Pain in Neurofibromatosis Type 1. Pain Pract. 2018 Mar 23.","10.1111/papr.12695","Plexiform Neurofibroma","Neurofibromatosis 1",null]},{"rowId":24,"versionNumber":12,"values":["Plexiform Neurofibroma Interactome","syn4939890","NTAP","Choi, K. et al. An inflammatory gene signature distinguishes neurofibroma SC and macrophages from cells in the normal peripheral nervous system. Scientific Reports. 2017 March 3.","10.1038/srep43315","Plexiform Neurofibroma","Neurofibromatosis 1",null]},{"rowId":25,"versionNumber":23,"values":["Mechanisms underlying cutaneous neurofibroma formation in NF1","syn4939910","NTAP","Peacock, JD et al. Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors. Cancer Res. 2018 Jul 1;78(13):3672-3687.","10.1158/0008-5472.CAN-17-3167","Cutaneous Neurofibroma","Neurofibromatosis 1","yes"]},{"rowId":26,"versionNumber":19,"values":["Screening of Plexiform Neurofibroma 3D Models","syn4939916","NTAP","Brock EJ, et al.  How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization. Mini Rev Med Chem. 2016","10.2174/1389557515666151001154002","Plexiform Neurofibroma","Neurofibromatosis 1",null]},{"rowId":27,"versionNumber":12,"values":["Determining pNF Cell Of Origin using iPS Cells","syn4939918","NTAP","Carrio, M et al. Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings. Hum Mutat. 2018 Aug;39(8):1112-1125. ","10.1002/humu.23552","Plexiform Neurofibroma","Neurofibromatosis 1",null]},{"rowId":28,"versionNumber":12,"values":["pNF Cell Line Development","syn7239479","NTAP","Li H., et al. Immortalization of human normal and NF1 neurofibroma schwann cells. Laboratory Investigation 2016 Oct; 96:11051115. ","10.1038/labinvest.2016.88","Plexiform Neurofibroma","Neurofibromatosis 1",null]},{"rowId":29,"versionNumber":12,"values":["NF1 Dermal Neurofibroma Longitudinal Natural History Study and Selumetinib Clinical Trial","syn8012530","NTAP","Cannon Al, et al. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study. Orphanet J Rare Dis. 2018 Feb 7;13(1):31. ","10.1186/s13023-018-0772-z","Cutaneous Neurofibroma","Neurofibromatosis 1",null]},{"rowId":30,"versionNumber":12,"values":["Plexiform Neurofibroma Model Systems for Preclinical Drug Screening","syn7217928","NTAP","Kraniak, JM et al.  Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening.  Exp Neurol. 2017 Oct 18","10.1016/j.expneurol.2017.10.012","Plexiform Neurofibroma","Neurofibromatosis 1",null]}]}},"selectColumns":[{"name":"projectName","columnType":"STRING","id":"70035"},{"name":"id","columnType":"ENTITYID","id":"70408"},{"name":"fundingAgency","columnType":"STRING","id":"62359"},{"name":"citation","columnType":"STRING","id":"70409"},{"name":"doi","columnType":"STRING","id":"70037"},{"name":"tumorType","columnType":"STRING","id":"39539"},{"name":"diseaseFocus","columnType":"STRING","id":"62360"},{"name":"featured","columnType":"STRING","id":"71578"}],"columnModels":[{"id":"70035","name":"projectName","columnType":"STRING","maximumSize":89},{"id":"70408","name":"id","columnType":"ENTITYID","facetType":"enumeration"},{"id":"62359","name":"fundingAgency","columnType":"STRING","maximumSize":4,"facetType":"enumeration"},{"id":"70409","name":"citation","columnType":"STRING","maximumSize":400},{"id":"70037","name":"doi","columnType":"STRING","maximumSize":44},{"id":"39539","name":"tumorType","columnType":"STRING","maximumSize":50,"facetType":"enumeration"},{"id":"62360","name":"diseaseFocus","columnType":"STRING","maximumSize":19,"facetType":"enumeration"},{"id":"71578","name":"featured","columnType":"STRING","maximumSize":3,"enumValues":["yes"]}],"facets":[{"concreteType":"org.sagebionetworks.repo.model.table.FacetColumnResultValues","columnName":"id","facetType":"enumeration","facetValues":[{"value":"syn4939874","count":1,"isSelected":false},{"value":"syn4939878","count":2,"isSelected":false},{"value":"syn4939888","count":4,"isSelected":false},{"value":"syn4939890","count":1,"isSelected":false},{"value":"syn4939896","count":1,"isSelected":false},{"value":"syn4939906","count":1,"isSelected":false},{"value":"syn4939910","count":1,"isSelected":false},{"value":"syn4939912","count":2,"isSelected":false},{"value":"syn4939916","count":1,"isSelected":false},{"value":"syn4939918","count":1,"isSelected":false},{"value":"syn7217928","count":2,"isSelected":false},{"value":"syn7239479","count":1,"isSelected":false},{"value":"syn8012530","count":2,"isSelected":false}]},{"concreteType":"org.sagebionetworks.repo.model.table.FacetColumnResultValues","columnName":"fundingAgency","facetType":"enumeration","facetValues":[{"value":"NTAP","count":20,"isSelected":false}]},{"concreteType":"org.sagebionetworks.repo.model.table.FacetColumnResultValues","columnName":"tumorType","facetType":"enumeration","facetValues":[{"value":"Cutaneous Neurofibroma","count":3,"isSelected":false},{"value":"Plexiform Neurofibroma","count":17,"isSelected":false}]},{"concreteType":"org.sagebionetworks.repo.model.table.FacetColumnResultValues","columnName":"diseaseFocus","facetType":"enumeration","facetValues":[{"value":"Neurofibromatosis 1","count":20,"isSelected":false}]}]}